CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism

Juliana Camacho-Pereira, Mariana G. Tarragó, Claudia C S Chini, Veronica Nin, Carlos Escande, Gina M. Warner, Amrutesh S. Puranik, Renee A. Schoon, Joel M Reid, Antonio Galina, Eduardo Nunes Chini

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

Nicotinamide adenine dinucleotide (NAD) levels decrease during aging and are involved in age-related metabolic decline. To date, the mechanism responsible for the age-related reduction in NAD has not been elucidated. Here we demonstrate that expression and activity of the NADase CD38 increase with aging and that CD38 is required for the age-related NAD decline and mitochondrial dysfunction via a pathway mediated at least in part by regulation of SIRT3 activity. We also identified CD38 as the main enzyme involved in the degradation of the NAD precursor nicotinamide mononucleotide (NMN) in vivo, indicating that CD38 has a key role in the modulation of NAD-replacement therapy for aging and metabolic diseases.

Original languageEnglish (US)
Pages (from-to)1127-1139
Number of pages13
JournalCell Metabolism
Volume23
Issue number6
DOIs
StatePublished - Jun 14 2016

Fingerprint

NAD
Nicotinamide Mononucleotide
NAD+ Nucleosidase
Metabolic Diseases
Enzymes
Therapeutics

Keywords

  • aging
  • CD38
  • glucose intolerance
  • mitochondrial function
  • NAD

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Physiology

Cite this

Camacho-Pereira, J., Tarragó, M. G., Chini, C. C. S., Nin, V., Escande, C., Warner, G. M., ... Chini, E. N. (2016). CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metabolism, 23(6), 1127-1139. https://doi.org/10.1016/j.cmet.2016.05.006

CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. / Camacho-Pereira, Juliana; Tarragó, Mariana G.; Chini, Claudia C S; Nin, Veronica; Escande, Carlos; Warner, Gina M.; Puranik, Amrutesh S.; Schoon, Renee A.; Reid, Joel M; Galina, Antonio; Chini, Eduardo Nunes.

In: Cell Metabolism, Vol. 23, No. 6, 14.06.2016, p. 1127-1139.

Research output: Contribution to journalArticle

Camacho-Pereira, J, Tarragó, MG, Chini, CCS, Nin, V, Escande, C, Warner, GM, Puranik, AS, Schoon, RA, Reid, JM, Galina, A & Chini, EN 2016, 'CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism', Cell Metabolism, vol. 23, no. 6, pp. 1127-1139. https://doi.org/10.1016/j.cmet.2016.05.006
Camacho-Pereira J, Tarragó MG, Chini CCS, Nin V, Escande C, Warner GM et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metabolism. 2016 Jun 14;23(6):1127-1139. https://doi.org/10.1016/j.cmet.2016.05.006
Camacho-Pereira, Juliana ; Tarragó, Mariana G. ; Chini, Claudia C S ; Nin, Veronica ; Escande, Carlos ; Warner, Gina M. ; Puranik, Amrutesh S. ; Schoon, Renee A. ; Reid, Joel M ; Galina, Antonio ; Chini, Eduardo Nunes. / CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. In: Cell Metabolism. 2016 ; Vol. 23, No. 6. pp. 1127-1139.
@article{8c26f607bcd24931b8732838a983518f,
title = "CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism",
abstract = "Nicotinamide adenine dinucleotide (NAD) levels decrease during aging and are involved in age-related metabolic decline. To date, the mechanism responsible for the age-related reduction in NAD has not been elucidated. Here we demonstrate that expression and activity of the NADase CD38 increase with aging and that CD38 is required for the age-related NAD decline and mitochondrial dysfunction via a pathway mediated at least in part by regulation of SIRT3 activity. We also identified CD38 as the main enzyme involved in the degradation of the NAD precursor nicotinamide mononucleotide (NMN) in vivo, indicating that CD38 has a key role in the modulation of NAD-replacement therapy for aging and metabolic diseases.",
keywords = "aging, CD38, glucose intolerance, mitochondrial function, NAD",
author = "Juliana Camacho-Pereira and Tarrag{\'o}, {Mariana G.} and Chini, {Claudia C S} and Veronica Nin and Carlos Escande and Warner, {Gina M.} and Puranik, {Amrutesh S.} and Schoon, {Renee A.} and Reid, {Joel M} and Antonio Galina and Chini, {Eduardo Nunes}",
year = "2016",
month = "6",
day = "14",
doi = "10.1016/j.cmet.2016.05.006",
language = "English (US)",
volume = "23",
pages = "1127--1139",
journal = "Cell Metabolism",
issn = "1550-4131",
publisher = "Cell Press",
number = "6",

}

TY - JOUR

T1 - CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism

AU - Camacho-Pereira, Juliana

AU - Tarragó, Mariana G.

AU - Chini, Claudia C S

AU - Nin, Veronica

AU - Escande, Carlos

AU - Warner, Gina M.

AU - Puranik, Amrutesh S.

AU - Schoon, Renee A.

AU - Reid, Joel M

AU - Galina, Antonio

AU - Chini, Eduardo Nunes

PY - 2016/6/14

Y1 - 2016/6/14

N2 - Nicotinamide adenine dinucleotide (NAD) levels decrease during aging and are involved in age-related metabolic decline. To date, the mechanism responsible for the age-related reduction in NAD has not been elucidated. Here we demonstrate that expression and activity of the NADase CD38 increase with aging and that CD38 is required for the age-related NAD decline and mitochondrial dysfunction via a pathway mediated at least in part by regulation of SIRT3 activity. We also identified CD38 as the main enzyme involved in the degradation of the NAD precursor nicotinamide mononucleotide (NMN) in vivo, indicating that CD38 has a key role in the modulation of NAD-replacement therapy for aging and metabolic diseases.

AB - Nicotinamide adenine dinucleotide (NAD) levels decrease during aging and are involved in age-related metabolic decline. To date, the mechanism responsible for the age-related reduction in NAD has not been elucidated. Here we demonstrate that expression and activity of the NADase CD38 increase with aging and that CD38 is required for the age-related NAD decline and mitochondrial dysfunction via a pathway mediated at least in part by regulation of SIRT3 activity. We also identified CD38 as the main enzyme involved in the degradation of the NAD precursor nicotinamide mononucleotide (NMN) in vivo, indicating that CD38 has a key role in the modulation of NAD-replacement therapy for aging and metabolic diseases.

KW - aging

KW - CD38

KW - glucose intolerance

KW - mitochondrial function

KW - NAD

UR - http://www.scopus.com/inward/record.url?scp=84975472602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975472602&partnerID=8YFLogxK

U2 - 10.1016/j.cmet.2016.05.006

DO - 10.1016/j.cmet.2016.05.006

M3 - Article

VL - 23

SP - 1127

EP - 1139

JO - Cell Metabolism

JF - Cell Metabolism

SN - 1550-4131

IS - 6

ER -